According to Satya Nadella on Twitter, Microsoft Research detailed GigaTIME, a multimodal AI system that generates virtual populations to model the tumor microenvironment at scale, enabling faster in silico hypothesis testing for oncology R&D; as reported by Microsoft Research Blog, GigaTIME integrates histopathology, genomics, and clinical data to simulate cell–cell interactions and treatment responses, showing improved prediction fidelity versus single‑modal baselines and reducing simulation runtime from days to hours (source: Microsoft Research Blog). According to Microsoft Research Blog, the platform supports population‑level counterfactual analyses and cohort stratification for trial design, creating potential business value for pharma by prioritizing targets, optimizing dosing, and de‑risking early-stage studies with synthetic cohorts; as reported by Microsoft Research Blog, benchmarking on multi-cancer datasets demonstrated better generalization to out‑of‑distribution cohorts and more stable effect-size estimates, indicating utility for precision oncology workflows.

According to Google DeepMind, AlphaGenome is their most advanced genomics AI model to date, now published in Nature. The model and its weights are available to academic researchers, enabling the scientific community to leverage advanced machine learning for improved DNA analysis and molecular impact prediction. As reported by Google DeepMind, AlphaGenome is expected to accelerate biological discoveries and drive innovation in genomics research.

According to Sundar Pichai, AlphaGenome has surpassed 1 million API calls from users in over 160 countries, highlighting its rapid global adoption and significant potential for accelerating scientific discovery. As reported by Sundar Pichai via Twitter, this milestone demonstrates the strong demand for advanced AI-powered genomics platforms and suggests expanding business opportunities for companies leveraging large language models and machine learning in life sciences.

According to Google DeepMind on Twitter, the company has made the AlphaGenome model and its weights publicly available to scientists worldwide, aiming to accelerate advancements in genomics research. This release provides researchers with direct access to cutting-edge AI technology for genomic analysis, fostering collaborative innovation and expanding business opportunities in biotechnology and healthcare applications. As reported by Google DeepMind, this move is expected to speed up the discovery of genetic insights and practical applications in precision medicine.

According to Google DeepMind, the AlphaGenome API is now processing over 1 million API calls daily from more than 3000 users across 160 countries. Researchers are leveraging this advanced model to address complex challenges in biology, highlighting its global reach and significant adoption in scientific research. As reported by Google DeepMind, the model's practical applications span genomics, drug discovery, and protein analysis, demonstrating tangible business opportunities for biotechnology and pharmaceutical companies seeking AI-powered solutions.